

Diagnosis

For men diagnosed between January - December 2025 in England and between January - December 2024 in Wales*

60,827 men were diagnosed with prostate cancer in England in 2025



7% increase compared with 57,029 men in 2024

2,700 men were diagnosed with prostate cancer in Wales in 2024



12% increase compared with 2,402 men in 2023

* The reporting periods are different due to data availability

SUMMARY: The numbers of men diagnosed with prostate cancer each year continue to rise in England and Wales

Disease presentation

For men diagnosed between January - December 2023 in England and between January - December 2024 in Wales

12% of men presented with **metastatic** disease in England

20% of men presented with **metastatic** disease in Wales

12% the previous year in England

20% the previous year in Wales

SUMMARY: The percentage of men diagnosed with metastatic (advanced) prostate cancer remains stable in England and Wales

Number of men who underwent prostate cancer treatment

For men diagnosed between January - December 2025 in England and between January - December 2024 in Wales

10,218 men underwent a **radical prostatectomy** in England in 2025



7% increase compared with 9,552 men in 2024 (England)

245 men underwent a **radical prostatectomy** in Wales in 2024*



22% decrease compared with 315 men in 2023 (Wales)

* Data issues identified which may affect the data quality and completeness for Wales in this audit

17,933 men underwent **radical prostate radiotherapy** in England in 2025**

** 10 months data from 1 January - 31 October 2025 (England)

606 men underwent **radical prostate radiotherapy** in Wales in 2024*



35% decrease compared with 935 men in 2023 (Wales)


* Data issues identified which may affect the data quality and completeness for Wales in this audit

SUMMARY: The numbers of men receiving radical treatment continue to increase in England, but have fallen substantially in Wales


Treatment allocation

For men diagnosed between January - December 2023 in England and between January - December 2024 in Wales

Low-risk, localised disease*




7% of men had radical treatments in England
7% the previous year




11% of men had radical treatments in Wales
7% the previous year

High-risk/locally advanced disease*



69% of men had radical treatments in England
69% the previous year



54% of men had radical treatments in Wales
68% the previous year

*T stage 1/2, Gleason ≤ 6 , M/N 0 or missing

*T stage 3/4, Gleason ≥ 8 , N1

SUMMARY: The percentage of men receiving overtreatment and undertreatment remains stable in England, but have risen and fallen respectively in Wales

Treatment outcomes (i.e. genitourinary or gastrointestinal complications)

For men undergoing surgery between April 2024 - March 2025 in England and Wales



12% of men were **readmitted** within 3 months **following surgery** in England
12% the previous year

21% of men were **readmitted** within 3 months **following surgery** in Wales
14% the previous year



SUMMARY: The percentage of men requiring emergency readmission to hospital following radical surgery remains stable in England, but has risen in Wales

For men undergoing radical treatment between September 2021 - August 2022 in England and Wales



In England, **6%** of men experienced at least one **genitourinary** complication requiring a procedural/surgical intervention within two years after **radical prostatectomy**

In Wales, **4%**



In England, **8%** of men experienced at least one **gastrointestinal** complication requiring a procedural/surgical intervention within two years after **radical radiotherapy**

In Wales, **7%**



In England, **5%** of men experienced at least one **genitourinary** complication requiring a procedural/surgical intervention within two years after **radical radiotherapy**

In Wales, **7%**



SUMMARY: In England, the percentages of men experiencing short- to medium-term urinary/bowel complications following radical treatment remains stable. In Wales, the percentages of men experiencing similar complications following radical surgery has fallen, but risen following radical radiotherapy.

Survival outcomes in metastatic disease

Newly diagnosed men with metastatic hormone-sensitive (advanced) prostate cancer in England between January 2015 - July 2022*

3-Year Overall Mortality

3-Year Prostate Cancer-Specific Mortality



* Data currently unavailable for Wales

SUMMARY: In England, an extra 1 in 10 men are alive at 3 years following a diagnosis of metastatic prostate cancer in 2022 compared to 2015

Please see our glossary of terms here.

Thanks for reading the patient summary of our 2026 State of the Nation report, if you would like further detail you can access our full report here.

If you're worried about prostate cancer or prostate problems, Prostate Cancer UK offer a range of services so you can choose what works for you. Click here to have a look.